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In this chapter, we present the founding framework of a novel theory termed as 
Cancer Evolution-Development (Cancer Evo-Dev), based on the current understand-
ing of hepatitis B virus (HBV) induced hepatocarcinogenesis. The interactions of 
genetic predispositions and HBV infection is responsible for the maintenance of 
chronic non-resolving inflammation. Under the inflammatory microenvironment, 
pro-inflammatory factors trans-activate the expression of cytidine deaminases and 
suppress the expression of uracil DNA glycosylase. The imbalance between the muta-
genic forces and mutation-correcting forces facilitates the generations of somatic 
mutations, viral mutations, and viral integrations into the host genomes. The major-
ity of cells with genomic mutations and mutated viruses are eliminated in survival 
competition. Only a small percentage of the mutated cells adapted to the hostile 
environment can survive, retro-differentiate, and function as cancer-initiating cells, 
representing a process of “mutation-selection-adaptation”. Cancer Evo-Dev lays the 
theoretical foundation for understanding the mechanisms by which chronic infection 
of HBV promotes hepatocarcinogenesis. This theory also plays an important role in 
specific prophylaxis, prediction, early diagnosis, and targeted treatment of cancers.
Keywords: Hepatocarcinogenesis, hepatitis B virus, inflammation, mutation, 
evolution
1. Introduction
Chronic infection of hepatitis B virus (HBV) is a major cause of hepatocel-
lular carcinoma (HCC). Although the strong etiologic relationship between HBV 
infection and HCC has been supported by substantial evidence, the underlying 
mechanism is still elusive. There are more than nine thousand studies investigat-
ing HBV-induced hepatocarcinogenesis, which yield 143 genes function in 137 
pathways [1]. Most of the studies are one-sided investigations, only a few trying to 
provide a theoretical hypothesis and to promote the system-level understanding of 
HBV-induced HCC (HBV-HCC). In past decades, continuous attempts have been 
made to investigate carcinogenesis from an evolutionary point of view. In 1976, Dr. 
Nowell first proposed that most neoplasms originate from a single cell. Malignant 
cells are more genetically unstable than normal cells [2] In 2006, it was pointed out 
Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach
2
that cancer clone genetic diversification and sub-clonal selection occurs within the 
microenvironment, which is similar to the process of Darwinian natural selection 
[3]. This viewpoint was put forward mainly based on morphological evidence 
and only a limited number of gene mutations and related signaling pathways were 
discussed. The widespread application of new generation sequencing promotes 
the investigation of genetic diversification and clonal selection within tissue 
ecosystems. It was found that the number of mutations in cancer range from 10 to 
hundreds of thousands. The majority of mutations are “passengers” and a small 
part are “drivers” [4]. Cancer cells acquire a variety of critical phenotypes via 
driver mutations, which compound to enhance the capabilities of self-renewal, 
migration, and invasion. The mutational spectra in cancers can reflect the charac-
teristics of the mutational process, including the error-prone repair and genotoxic 
exposure [5]. Interestingly, the cytidine deaminase induced mutation is dominant 
in most cancers [6]. Cytidine deaminase is upregulated during inflammation and 
defense against many viruses, including HBV. Epidemiological and experimental 
evidence identified the co-evolution of HBV and cancer cells during chronic 
inflammation. In turn, the mutant cells and viruses also affect the inflammatory 
microenvironment [7]. Thus, there is a similarity between the process of carcino-
genesis and Darwinian evolution. Furthermore, the investigation of cancer evolu-
tion can draw upon the understanding of developmental processes. Development 
is referred to the process that a fertilized egg develops into an individual. In 
humans, the fertilized diploid cell differentiates into various functional and/or 
structural cells to form different organs and tissues within 40 weeks. This process 
resembles the process of long-term organic evolution morphologically, from single 
cell creatures to multicellular creatures, and from aquatic creatures to terrestrial 
mammals. Some evolutionarily conserved molecules, like Hedgehog, HOX, and 
Myc are essential for the developmental process, suggesting evolution and devel-
opment have similar inherent mechanisms [8–11]. The integration of evolution 
and developmental biology was termed Evo-Devo [12, 13]. In this chapter, we 
present a scientific theory of Cancer Evolution-Development (Cancer Evo-Dev) 
based on the current understanding of HBV-HCC [14]. This theoretical hypothesis 
can provide an evolutionary insight of profiling HCC risk and developing more 
reasonable predictive and prognostic strategies.
2. Framework of Cancer Evo-Dev
The synergetic effects of genetic predisposition and environmental factors 
contribute to the imbalance of the immune system, resulting in the activation and 
maintenance of non-resolving inflammation, that functions as the microenviron-
ment for the Cancer Evo-Dev. Activated inflammatory signaling pathways can 
trans-activate the expression of nucleic acid editing enzymes, such as the human 
apolipoprotein B mRNA-editing enzyme catalytic polypeptides (APOBECs) family, 
thus promoting viral and somatic mutations. Viral mutants facilitate the malignant 
transformation of normal cells. Most mutant cells are eliminated under the selec-
tive pressure of the inflammatory microenvironment, while a small proportion of 
mutated cells survive. These survived mutant clones evolve to tumor-initiating cells 
by altering the original cell signal patterns, promoting epithelial-mesenchymal 
transition (EMT), or reprogramming the metabolic patterns, etc. Some established 
cancer markers, such as α-fetoprotein (AFP) and carcinoembryonic antigen (CEA), 
are usually expressed at the embryonic stage, silenced after birth, and re-expressed 
in cancer patients. These pieces of evidence imply that the process of Cancer Evo-
Dev can be characterized as “backward evolution” and “retro-differentiation”.
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3. Chronic inflammation is indispensable for HBV-HCC evolution
As a defense mechanism responding to exogenous infection and injury, acute 
inflammation is beneficial to humans. However, chronic inflammation, also termed 
non-resolving inflammation is essential for carcinogenesis. The weak immunity, 
HBV mutation, and HBV genotype contribute to the chronicity of inflamma-
tion. During the development of HBV-induced HCC evolution, non-resolving 
inflammation is evident. By relieving hepatic inflammation, antiviral therapy 
can significantly lower the risks of HCC occurrence and postoperative recurrence 
[15, 16]. Interestingly, the risk of HCC is still significantly higher in the complete 
responder group of oral-administered antiviral therapy, compared with the subjects 
with inactive chronic hepatitis B (CHB) [17]. The active inflammation on chronic 
infection background also indicated postoperative recurrence [18, 19]. The close 
association between chronic inflammation and the risk of HCC can be explained 
from the perspective of Cancer Evo-Dev. Cancer evolution is based on two condi-
tions: the continuous acquisition of somatic mutations and natural selection acting 
on the resultant phenotypic diversity [20]. These two conditions were fulfilled by 
HBV infection-induced chronic inflammation, that induces mutagenic factors such 
as APOBECs and provides selection pressure.
3.1 Chronicity of HBV infection and hepatic inflammation
The oncogenic capability of HBV is closely related to its capacity to induce and 
maintain chronic inflammation. The chronicity of HBV infection is dependent on 3 
aspects: infection occasion, HBV genotypes, and genetic predisposition of the key 
immune molecules. HBV infection in early childhood is generally believed to be one 
of the major causes of chronic HBV infection in adulthood. The perinatal infection 
occurred in 8.7% and 84.2% of infants born to hepatitis B e-antigen (HBeAg)-
positive mothers who did and did not receive immunoprophylaxis, respectively. The 
infection rates were 0.4% and 6.7% for infants born to HBeAg-negative mothers 
and HBeAg-positive mothers, respectively. Furthermore, the chronicity of HBV 
infection acquired perinatally was 28.2% and 64.5% for infants born to HBeAg-
negative mothers and HBeAg-positive mothers, respectively [21]. This vulnerability 
of infants may due to the immaturity of the immune system. Although perinatal 
HBV infection is an important cause of chronic HBV infection, the chronic trans-
formation of acute hepatitis B is the predominant cause of chronic HBV infection 
in adults. In China, 8.5% of patients with acute hepatitis B develop into chronic 
HBV infection 6 months after acute infection [22]. The HBV genotype and genetic 
predisposition of immune molecules contribute to this transformation.
According to sequence divergence of 8% in the whole viral genome, HBV can 
be classified into eight genotypes (A to H) [23]. Variant genotypes are distributed 
unevenly around the world, and the predominant one in mainland China is geno-
type C (68.3%), followed by genotype B (25.5%) [24]. Under selection pressure 
from the inflammatory microenvironment, the fates of different HBV genotypes 
are distinct. Genotype B HBV is prone to causing acute infection, whereas genotype 
C HBV is associated with chronic infection and contributes independently to the 
development of HCC [22, 25, 26].
The genetic predisposition of immune molecules is the third major cause of 
chronic HBV infection. The single nucleotide polymorphisms (SNPs) in the loci 
encoding human leukocyte antigen class II (HLA-II) are significantly associated 
with vaccine response as well as the risk of CHB, HBV-induced liver cirrhosis, and 
HBV-HCC [27–32]. Interestingly, the allele frequencies of SNPs affecting the expres-
sion of HLA-DP and HLA-DQ are variant in different human races. The polymorphic 
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genotypes that are more frequent in the Han Chinese than in European populations 
are significantly associated with the increased risk of chronicity of HBV infection 
as well as the immune selection of HBV mutations related to end-stage liver diseases 
[21]. These data suggest that the Han Chinese are inherently more apt to progress 
into chronic infection once exposed to HBV infection than Europeans. This might be 
partly responsible for the fact that chronic HBV infection, HBV-induced liver cirrho-
sis, and HBV-HCC are more frequent in Chinese than in European populations. The 
genetic polymorphisms of HLA-II may facilitate the progression of CHB into HCC 
through predisposing immune imbalance and maintain HBV infection. Due to the 
chronicity of inflammation, the mutagenic force that serves as antiviral immunity is 
prone to injury the human genome, thus induce Cancer Evo-Dev.
3.2 HBV promote the generation of inflammatory mutations
The APOBECs are powerful endogenous mutagenic factors that can catalyze 
irreversible cytidine and deoxycytidine deamination to convert bases from cytosine 
to uracil, creating a cytosine-to-uracil mismatch in minus-strand and reverse-
transcript G-to-A (guanosine-to-adenosine) transitions in plus-stranded DNA. 
APOBEC3s play important roles in the innate immune system [7]. Mutagenesis 
mediated by APOBEC3s can increase the viral mutation load to a level that exceeds 
the threshold for viral viability. Accordingly, APOBEC3s can similarly increase 
the number of somatic mutations to a threshold that exceeds the host’s repair 
ability and starts the Cancer Evo-Dev. Three mechanisms prevent the induction of 
somatic mutations by the APOBEC3s family. First, APOBEC3s rarely express in 
normal tissues, and short-term activation of APOBEC3s is beneficial for eliminat-
ing pathogens. Second, the cytidine deaminase activity of APOBEC3s is applied 
almost exclusively to single-stranded nucleotides, in which mutagenesis is 200–300 
times more efficient than it is in double-stranded DNA. Third, the uracil-induced 
mutagenesis of APOBEC3s is counteracted by uracil–DNA glycosylase (UNG), that 
plays an important role in the base-excision repair mechanism [7, 33]. However, 
genetic susceptibility, viral mutations, and an unbalanced immune system interact 
with each other to prevent the absolute elimination of HBV, resulting in chronic 
inflammation accompanied with APOBEC3s expression. During the HBV-induced 
malignant transformation, inflammatory signaling pathways including interleukin 
6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) and tumor 
necrosis factor α (TNF-α)/ nuclear factor kappa B (NF-κB) are activated, which 
up-regulate the expression of APOBEC3s [7]. Among the members of APOBEC3s, 
APOBEC3B was identified as the major subtype responsible for the APOBEC-
signature somatic mutations in multiple cancers [34]. The mutagenic effect of 
inflammatory factors on the HBV genome depends on the degree of the damage 
to the APOBEC3B–UNG balance. IL-6 can increase the expression of APOBEC3B 
and decrease the expression of UNG. The functional polymorphisms located in the 
APOBEC3B promoter (rs2267401-G) and UNG enhancer (rs3890995-C) predispose 
the IL-6 induced APOBEC3B-UNG imbalance and increase the risk of HCC [35].
3.3 HBV affects the selection pressure of the inflammatory microenvironment
In an inflammatory microenvironment, continuous necrosis and proliferation 
can help to accumulate somatic mutations, and tumor-initiating cell clones with 
strong viability are selected. HBV replication directly reflects the selective stress 
and influences the evolution of HCC. It has been revealed by various studies that 
HBV DNA load increases the risk of HCC in CHB patients [25, 36]. A high level of 
HBV DNA load either in serum or liver tissue predicts poor postoperative prognosis 
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in HCC [37]. Meanwhile, HBV in turn affecting the selective pressure of the inflam-
matory microenvironment. The innate immune and adaptive immune against HBV 
are both participate in the selection of malignant cells. During the chronic infection 
of HBV, APOBEC3B is stimulated and reduces the occupancy of H3K27me3 on 
the promoter of CC-chemokine ligand 2 (CCL2). By this mechanism, APOBEC3B 
upregulates the CCL2 to enhance the recruitment of tumor-associated macrophages 
(TAMs) and myeloid-derived suppressor cells (MDSCs). TAMs and MDSCs sup-
press the function of CD8+T cells and are associated with a poor prognosis of HCC 
[38]. HBV can transmit into natural killer (NK) cells through exosomes, thereby 
inducing the disfunction of NK cells, which promotes the HCC evolution [39, 40]. 
HBV also induced the exhaustion of HBV-specific CD8+ T cells through impairing 
the mitochondrial functions, including electron transport, membrane transport, 
and the transcription of mitochondrial DNA [41]. The glucose metabolism of T cells 
is reprogramed by HBV, which leads to increased lactate production and decreased 
migration of T cells [42]. During chronic infection, HBV promotes the recruitment 
of regulatory T cells (Tregs) through activating the growth factor-beta (TGF-β)/
miR-34a/ CC-motif chemokine ligand 22 (CCL22) axis [43]. The increased Tregs 
suppress HCC antigen-specific immune responses and HBV antigen-specific 
immune response at the same time [44]. Thus, the HBV that survives the survival 
competition can in turn affect the inflammatory microenvironment.
4. Roles of HBV mutation during the process of HCC evolution
During HBV-induced hepatocarcinogenesis, viruses also experience the process 
of evolution. Viral evolution serves as a valuable clue to investigate the mechanism 
underlying the HBV-HCC [45]. The generation and accumulation of HBV mutations 
abide by the Darwinian model: mutation-selection–adaptation. In the inflammatory 
microenvironment, most HBV mutants are eliminated by the antiviral immune 
response. Only a tiny fraction of mutant viruses that facilitate the regeneration of 
hepatocytes can survive and gradually develop into the HCC-promoting clones.
4.1 The generation of HBV mutation
Two major mechanisms are responsible for the generation of HBV mutation. The 
first pattern is the replicative errors. During viral replication, the partially double-
stranded HBV DNA is generated from an intermediate RNA through the reverse 
transcription activity of the viral polymerase. Due to lack of proofreading capacity, 
the HBV genome has a higher mutation rate than other DNA viruses, which is in 
the range of 1.5 × 10−5 to 5 × 10−5 nucleotide substitutions per site per year, which 
can increase after HBeAg seroconversion [46]. The second viral mutation pattern is 
induced by host cytidine deaminases [7]. The APOBEC family has a dual effect on 
HBV: reduction of HBV and induction of HBV mutations [47]. The expression levels 
of APOBEC3s are positively correlated with the quasispecies complexity of HBV 
[48]. The genetic polymorphisms predisposing the IL-6 induced APOBEC3B-UNG 
imbalance significantly promote the generation of HCC related HBV mutations 
[35]. Although many HBV genome fragments, including the Enhancer II (EnhII) /
basal core promoter (BCP)/ precore region and the S region, are generally sensi-
tive to editing by members of APOBEC3 [49–53], the sequence encoding HBV X 
protein (HBx) is more vulnerable. APOBEC3 prefers the HBx region as its editing 
target and generates carboxylic acid–terminal truncated HBx (Ct-HBx). Although 
most HBV mutations are random, the directional evolution of HBV occurs under 
the selective pressures of chronic inflammation. In the immune tolerance phase of 
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chronic infection, the immune pressure is weak, and most of the individual viruses 
are wild-type. Immune pressure increases with the progression of chronic inflam-
mation, which facilitates the gradual occurrence of viral mutations, especially in 
HBeAg-negative individuals [54, 55]. HCC-related HBV mutations are selected by 
the immune microenvironment before the occurrence of HCC and can be used as 
predictive markers. Single-nucleotide polymorphisms of the inflammatory signal-
ing pathway genes, including STAT3, NF-κB, HLA-DP, and HLA-DQ have been 
demonstrated to maintain the chronic infection and to facilitate the selection of 
HCC-related HBV mutations that contribute to the risk of liver cancer [32, 56, 57]. 
However, those viral mutants that affect the pre-cancer hepatocytes are less infec-
tious to normal liver cells, which leads to a process of “dead-end” evolution.
4.2 The “dead-end” evolution of HBV
Hepatitis B virus belongs to the Hepadnaviridae family and is evolutionarily 
conservative in the long-term evolution of species [58]. However, the evolution 
of the HBV genome is evident in infected individuals during chronic infection. 
Previous research by our group established the wild-type HBV sequences of HBV 
subgenotypes B2 and C2, based on the whole HBV genome sequenced using 1000 
asymptomatic carriers of the HBV surface antigen from community-based epide-
miologic surveys. Based on the wild-type HBV sequences, HCC-related mutations 
and their development patterns were subsequently identified. We also observed that 
HBV mutations posing a significant HCC risk are located mainly within the BCP 
and preS regions [59–61]. During the HBV-induced carcinogenic “trilogy” (chronic 
hepatitis, liver cirrhosis, HCC), the species and frequencies of those mutations 
often accumulate consecutively and can be used to predict the occurrence and 
development of liver cirrhosis and HCC [15, 32, 56, 62]. Retrospective and prospec-
tive cohort studies have both identified a combination of HBV mutations (C1653T, 
A1762T/G1764A, and T1753V) that have significant predictive value [32, 63, 64]. 
Among them, the A1762T/G1764A mutation usually appears in the early stage; 
other mutations, including T1753V, C1653T, preS deletion, are evident only in a late 
stage of the evolution [65]. Reaction to chronic HBV infection (characterized by the 
immune response–induced hepatocyte injury and release of transaminase) is usually 
accompanied by HBeAg seroconversion and an increase in HBV mutations, indicat-
ing the selective effect of immune cells on viral mutants. The deficiency of CD8+ T 
cell epitopes is one of the main features of HBV mutations. The mutant virus with 
a low density of CD8+ T cells epitopes can evade immune eradication [66, 67]. The 
proportion of mutant preS/S region is higher in patients with occult HBV infection 
than in CHB patients [67, 68]. Therefore, CD+8 T cell is essential for the immune 
selection of HCC-related HBV mutants.
Hepatitis B virus acquired during infancy or early childhood, or at the early 
infection stage in adults, is usually the wild type [15, 32, 56]. During the chronic 
inflammation process, especially after an HBeAg shift from HBeAg-positive to 
HBeAg-negative, mutant HBV subgroups gradually increase. Although the HCC-
related HBV mutants are present in fetal cord blood, neonatal infection is usually 
caused by wild-type HBV rather than by mutant subgroups. At 1–15 years in 
HBV-infected children, the frequencies of HCC-related mutations increase with 
increasing age. However, compared with their mothers, who have been exposed to 
chronic infection for at least about 25 years, the children have fewer HCC-related 
HBV mutations [65]. The foregoing results are based on analyses of serum HBV. In 
individuals with chronic HBV infection, most all HBV is synthesized in hepatocytes 
and released into the circulation at a pace of up to 1011 viral particles daily [69]. 
The immune microenvironment of circulation, tumor tissue, and tumor-adjacent 
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liver tissue are all necessary for the HBV evolution [48]. Interestingly, HBV evolves 
more advanced in the sera than in the tumors of HCC patients. The evolutionary 
similarity between the sera-derived HBV strains and adjacent tissue-derived ones 
is significantly stronger than that between sera-derived HBV strains and tumor-
derived ones [48]. Although tumor-adjacent tissues are pathologically categorized 
as “normal,” they are typical precancerous lesions and have already entered the 
middle stage of the cancer evolutionary process. The HCCs that relapse more than 
2 years after resection are considered to be recurrent HCC and not a result of the 
initial HCC cell diffusion into remnant liver tissue [18]. The species and frequencies 
of certain HBV mutations in adjacent tissues are distinct in the different popula-
tions. Together with immune markers and expression levels of inflammatory genes, 
they can therefore be used to predict prognosis in HCC patients receiving curative 
surgery. For example, HBV mutations in the EnhII/BCP/PreC region, such as 
A1762T/G1764A, can serve as predictive markers for survival and recurrence [18], 
indicating that HBV evolution in adjacent tissues continues until the patient dies. 
Antiviral therapy can block HBV evolution in adjacent tissues by easing inflamma-
tion and notably prolongs survival in HCC patients [15].
Taken together, the Hepadnaviridae family members are highly conservative 
across species [65]. Wild-type HBV has the advantage of infecting hepatocytes, 
facilitating viral spread from one individual to another, and contributing to the 
maintenance of its viral species. The HCC-related mutants can cause malignant 
transformation but have lost the advantage of person-to-person infection. Those 
mutants are therefore usually eliminated at the death of the carriers, which is 
termed “dead-end” evolution.
4.3 High-risk HBV mutations promote the Cancer Evo-Dev
During hepatocarcinogenesis, high-risk HBV mutations are selected by the 
immune microenvironment. Because of overlapping open reading frames, HBV 
mutations altering the genes necessary for viral replication are unlikely transferred 
into their progeny viruses. Natural selection ensures only the fittest survive to 
pass their genes on to the next generation. Thus, the random natural mutations 
are therefore constrained to special regions of the HBV genome, especially in the 
fragment of HBx gene and large envelope protein gene fragment (preS1/preS2/S). 
These HBV mutations that survive the selective pressure can promote the evolution 
of HCC, which is supported by many pieces of evidence from epidemiology studies 
and mechanism studies.
Previous longitudinal studies, especially cohort studies, support that combo 
HBV mutations including A1762T/G1764A, C1653T, and T1753V in HBx gene in 
sera can predict the occurrence of HCC [64, 70]. The mutations in the HBV preS 
fragment, including the preS deletion, accumulate during the process of inflam-
mation-HCC transformation, which is significantly associated with increased risk 
of HCC [62, 71, 72]. Epidemiological evidence identified the interaction effect 
between HBV mutations and genetic polymorphisms of immune molecules. For 
the population with the infection of genotype B HBV, the SNPs of HLA-DP, includ-
ing rs3077 (T allele), rs2281388 (T allele), rs3135021 (G allele), and rs9277535 
(G allele) can promote the HBV persistence and are associated with a higher 
prevalence of HBV mutation increasing HCC risk. Moreover, the effects of HBV 
mutations on HCC risk are selectively significant in subjects with these HLA-DP 
SNPs that promote HBV persistence [32]. For the population with the infection 
of genotype C HBV, the HLA-DQ SNP, rs9275319 (GG genotype), is significantly 
associated with an increased prevalence of preS1 start codon mutation, an HCC-
risk mutation [63]. The SNPs of STAT3 SNPs appear to promote HCC evolution 
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in the host with HBV mutations [56]. The interaction effect of STAT3 rs1053004 
with T1674C/G and the interaction effect of STAT3 rs4796793 with preS2 start 
codon mutation are both significantly associated with an increased HCC risk. The 
T allele of rs223406 impairs the promoter activity of NFKBIA, a key molecule of 
the NF-κB signaling pathway. The interaction of rs223406 T allele with A1762T/
G1764A is significantly associated with an increased risk of HCC [57]. The genetic 
polymorphisms predisposing the imbalance of APOBEC3B and UNG increase the 
risk of HCC through through facilitate the generation of APOBEC3B-signature 
HBV mutations. Furthermore, the positive rate of APOBEC-signature HBV muta-
tions consecutively increased from asymptomatic HBsAg carrier (ASC) to HCC in 
HBV-infected subjects [35]. This line of evidence highlights the important role of 
HBV mutation in the process of HCC evolution.
Experimental evidence also confirms that HBV mutation can endow the hepato-
cytes with a survival advantage. The HBx with A1762T/G1764A–based combo muta-
tions can upregulate the expression of S-phase kinase-associated protein 2 (SKP2) 
by activating E2F1, a transcription factor, downregulate cell cycle inhibitors, and 
facilitate the ubiquitin-mediated proteasomal degradation of p21, thereby enhancing 
the proliferation of HCC cells [73, 74]. Moreover, HBx with A1762T/G1764A–based 
combo mutations also enhance the cell migration through activating the Wnt/β-
catenin signaling pathway [75]. Ct-HBx mutation can promote cell metastasis and 
invasiveness by activating the C-Jun/matrix metalloproteinase protein 10 signal-
ing pathway [15, 76]. The HBx gene with K130M/V131I mutations enhances HCC 
evolution by activating the arachidonic acid metabolism and the hypoxia-inducible 
factor-1a [77, 78]. Besides the mutated HBx gene, the mutated preS1, preS2, and S 
regions also notably facilitate carcinogenesis [18, 61]. The preS2 region with F141L 
can significantly downregulate the expression of the p53 pathway and upregulate the 
expression of cyclin-dependent kinase 4 and cyclin A, thereby promoting prolifera-
tion and colony-forming rates [79]. The accumulation of mutant envelop protein 
in the endoplasmic reticulum (ER) leads to the activation of ER stress signaling 
pathway [80]. ER stress promotes HCC evolution through generating reactive oxygen 
species (ROS), inducing oxidative DNA damage, and ultimately increasing genomic 
instability [81, 82]. Although HBV mutation plays important role in hepatocarcino-
genesis, somatic mutation of the human genome is the direct cause of cell evolution.
5. Roles of somatic mutation during the process of HCC evolution
The spontaneous rate of somatic mutations is not high enough to trigger the 
evolution process. HBV participates in the alteration of the host genome, both directly 
and indirectly. First, HBV can cause somatic mutations by directly integrating into the 
human genome. Second, mutant HBV contributes to the maintenance of non-resolv-
ing inflammation, that induces long-term up-regulation of APOBECs [7]. Somatic 
mutations can be classified according to their effects on Cancer Evo-Dev. A small 
proportion of the mutations can lead to advantageous phenotypes that are positively 
selected during the evolution process and thus are called “driver” mutations. The 
remaining mutations are “passengers” that contribute very little to carcinogenesis [4]. 
Due to survival competition and the positive selection of the inflammatory microenvi-
ronment, driver mutations accumulate sufficiently to promote malignant transforma-
tion. The distribution, combination, and dynamic patterns of driver mutations reflex 
the pressure of microenvironmental selection and growth advantage of cell subsets. 
As HCC has many etiological causes and experiences a long evolutionary process, the 
somatic mutation spectrum is most heterogeneous [6, 83]. The driver somatic muta-
tions affect multiple functions, like signaling pathways, EMT, and energy metabolism.
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5.1 Somatic mutations alter “stem-ness” signaling pathways
Based on the investigations of whole-exome sequencing, it is found that the 
somatic mutation in HCC evolution mainly altering six cancer related pathways: 
signaling pathway related with telomere maintenance, Wnt/b-catenin pathway, P53 
and cell cycle pathway, oxidative stress pathway, epigenome modifiers, RAS/RAF/
mitogen-activated protein kinase pathway, and PI3K/AKT/mTOR pathways [84]. 
Among them, the somatic mutation related to telomeres pathway is most frequent. 
Telomerase is activated in more than 90% HCC patients. Somatic mutation within 
the promoter of telomerase reverse transcriptase (TERT) is the major cause with 
the prevalence ranging from 54–60%. The second cause is the HBV integration  
in the TERT promoter, which is observed in 10–15% of HCC patients. Interestingly, 
the mutation of catenin beta 1 (CTNNB1) is more frequent in hepatitis C virus 
induced HCC, indicated a different way of Cancer Evo-Dev [85, 86]. The frequen-
cies of mutation in other hot genes range from 5–20%. Although the spectrums 
and frequencies of altered genes vary greatly among individuals, they are usually 
clustered to pathways or functional groups that are closely related to stem-ness 
and embryonic characteristics. In this regard, global mutation rates of functionally 
related genes are added together to define the mutation rate of a given signaling 
pathway. Mutation rates of Wnt/β-catenin, p53/cell cycle control, JAK/STAT, and 
PI3k/mTOR pathways range from 12–72%. Similar outstanding outcomes are also 
observed in functional gene groups of chromatin remodeling and telomere mainte-
nance. Therefore, it is promising to use combo somatic mutations as predictive and 
prognostic biomarkers just like gene signatures [19].
5.2 Somatic mutations affect HCC evolution through regulating EMT
APOBECs can promote gene demethylation and remove epigenetic memory to sta-
bilize the pluripotent state in embryonic stem cells through deaminating 5-methylcy-
tosine (5mC) or 5-hydroxymethylcytosine (5hmC) [87, 88]. EMT is a landmark event 
of Cancer Evo-Dev, which is driven by transcription factors, like ZEB1, ZEB2, SNAI1, 
and SNAI2. AID, a member of the APOBECs family, is upregulated by inflamma-
tory signals and induces demethylation of the promoters of ZEB1, ZEB2, SNAI1, and 
SNAI2. Silencing AID leads to increased methylation of CpG island proximal to the 
promoters of these EMT regulators, thus inhibits EMT and invasion of cells [89]. AID-
induced, CpG methylation-dependent mutagenesis is proven to be a common feature 
of cancer evolution [90]. Therefore, it is reasonable to postulate that re-expression of 
embryonic factors in cancers might result from epigenetic reprogramming caused by 
APOBECs family, that is upregulated by proinflammatory factors.
5.3 Somatic mutations reprogram energy metabolism
To support the rapid growth of malignant cells, tumor tissues prefer to use 
glycolysis for energy production, even in the presence of oxygen. Glucose is more 
easily to be metabolized to lactate in tumor tissues than in normal tissues. This pat-
tern of energy metabolism was identified in 1920 and was termed as Warburg effect 
[91]. Warburg effect in TAMs promotes vascular network formation, augments 
extravasation of tumor cells out of blood vessels, and induces higher levels of EMT 
at inflammatory foci within the tumor [92]. In the microenvironment with both 
hypoxia and hypoglycemia, stem cell-, angiogenic-, and EMT-biomarkers, as well 
as glycoprotein-P content and invasiveness of cancer cells are enhanced [93]. Thus, 
we believe that the Warburg effect promotes the evolutionary process of cancer 
under both hypoxia and hypoglycemia conditions. The Warburg effect can provide 
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essential energy for cell survival in a hostile microenvironment, furthermore, 
glycolysis generates the raw material for DNA synthesis of progeny cells. HBV 
infection and somatic mutation are both the possible origin of Warburg phenotype. 
In HBV-HCC, the major pattern of single nucleotide variants in mitochondrial 
DNA (mtDNA) is C > T, that is the character of APOBEC induced mutation. This 
kind of mutation mainly occurs in the D-loop region of mtDNA and promotes 
the proliferation, invasion, and metastasis of HCC cells [94]. Pyruvate kinase M2 
(PKM2), an alternatively spliced variant of the pyruvate kinase gene that is pref-
erentially expressed during embryonic development and in cancer cells, alters the 
final rate-limiting step of glycolysis, resulting in the cancer-specific Warburg effect 
[95]. Besides the Warburg effect, HCC cells also enhance other patterns of energy 
metabolism during evolution. For example, the inactivating mutation of ribosomal 
S6 kinase 2 (RSK2) can support cholesterol metabolism in HCC [96].
5.4 HBV integration
HBV integration is a kind of somatic mutation that is specific to the HBV-
induced Cancer Evo-Dev. Although the HCC in an individual can be monoclonal, 
HBV integration is common in most clones, indicating it is the early driver event for 
HCC evolution [83]. The HBV integration can be detected in 85–90% of HBV-HCC 
patients [97]. Moreover, the prevalence of HBV integration is 60–75% in HCCs from 
patients with occult HBV infection, indicating the HBV integration contributes 
to the occult HBV infection induced HCC [98, 99]. Approximately five thousand 
HBV integration events have been reported and more than half of them locate in 
the intergenic regions. Only the HBV integration events within thirteen genes are 
repeated in diverse studies [1]. TERT, mixed-lineage leukemia 4 (MLL4), fibronec-
tin 1 (FN1), cyclin E1 (CCNE1), and cyclin A2(CCNA2) are the top five most fre-
quently integrated genes [85, 100–105]. The X and core genes of HBV are the regions 
that most frequently insert into the human genome [103, 105]. Cis-activation of host 
genes is an important mechanism by which HBV integration promotes HCC evolu-
tion. The highest frequency of HBV integration is observed in the promoter region 
of TERT [85, 100–105]. The HBV integration within the TERT promoter leads to an 
increased mRNA level of TERT, that is significantly associated with a poor progno-
sis of HCC [103, 105]. MLL4 is the second most frequently integrated gene and the 
HBV integration mainly locate in the introns and exons [85, 105]. Since MLL gene 
family has methyltransferase activity, the HBV integration within MLL4 may pro-
mote HCC evolution in an epigenetic way. As the third most frequently integrated 
gene, FN1 is reported to create a microenvironment promoting metastasis of lung 
cancer [106]. Most HBV integration events within FN1 are detected in the adjacent 
tissues of HCC, indicating these mutations may contribute to the microenvironment 
of the early stage of HCC evolution [85, 101]. HBV integration is associated with an 
increased expression of CCNE1, that is reported to promote hepatic inflammation 
and hepatocarcinogenesis [107]. The HBV-CCNA2 chimeric transcript encodes 
a chimeric protein promoting cell cycle progression [108]. Besides affecting the 
expression or function of coding genes, HBV integration within the region of long 
interspersed nuclear elements (LINEs) can generate HBx-LINE1 chimeric transcript 
acting as long non-coding RNA (lncRNA). This lncRNA increases the activity of 
the Wnt pathway through decrease the level of miR-122 [104]. The DNA fragment 
with HBV integration can be used as a circulating biomarker of HCC recurrence. 
The HBV-host chimera DNA can be detected in more than 90% of HCC patients 
before surgery. After the surgery, HBV-host chimera DNA can still be detected in 
20% of HCC patients, which may come from the mutant hepatocytes at the early 
stage of evolution and are significantly associated with HCC recurrence [109]. Thus, 
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most HBV integration occurs randomly. The integration mutations that endow the 
hepatocytes with survival advantage will have the opportunity of accumulation.
As mentioned above, hepatocarcinogenesis involves the co-evolution of HBV 
and transformed cells. The interaction between somatic mutation and HBV muta-
tion occurs during this process. The deletion, duplication, and translocation are 
observed near the insertion site of integrated HBV fragments [84]. The frequency 
of HBV mutation is positive associated with the level of HBV integration. The 
prevalence of HBx mutation is significantly higher in patients with HBV integration 
in TERT promoter (35%) than in patients without these integration events (19.8%) 
[83]. There are studies reporting the selective expression of mutant HBx and preS2 
genes in the tumor tissues from patients with occult HBV infection [110]. These 
pieces of evidence support that the integration and selection of mutant HBV frag-
ments play important roles in the HCC evolution.
6. Conclusion
Based on studies of HBV-induced hepatocarcinogenesis (a typical evolutionary 
process), we put forward the theory of Cancer Evo-Dev. Under conditions of genetic 
predisposition, exogenous factors such as viral infection can induce chronic inflam-
mation. The elimination of chronic infection can relieve inflammation, reducing the 
incidence of cancer and subsequently extending effective survival. As the theory 
describes, tumor-initiating cells obtain survival advantage during the evolutionary 
process of mutation-selection–adaptation by activating a “stem-ness” pathway and 
simultaneously causing evolutionary heterogeneity. Critical molecules in a functional 
subnetwork that maintains and promotes the Cancer Evo-Dev process can be dem-
onstrated using systems biology approaches. The development of high-efficiency 
inhibitors that will target these critical molecules and block corresponding signal 
pathways could be a powerful treatment strategy in advanced cancers. The theory of 
Cancer Evo-Dev will serve three purposes: first, the early prevention that reduces the 
cancer incidence and delays its onset; second, targeted therapy that reduces morbid-
ity and mortality rates. Therefore, this theory can contribute to the realization of “P4 
pattern” medicine (predictive, preventive, personalized, and participatory).
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